TARGET DOSES OR TARGET PARAMETERS: WHAT IS PIVOTAL FOR CARDIOVASCULAR RISK DECREASE?
https://doi.org/10.18705/1607-419X-2013-19-3-204-211
Abstract
The article reviews the up-to-date approaches to the secondary prevention of cardiovascular complications, and the clinical situations when the target drug doses or target parameter levels are important to achieve an effect. We discuss the role of available evidence in titrating doses of angiotensin-converting enzyme inhibitors, statins and beta-blockers.
About the Authors
S. R. Gilyarevskiy
Russian Medical Academy of Advanced Studies, Moscow
Russian Federation
Corresponding author: Russian Medical Academy of Advanced Studies, 2/1 Barrikadnaya st., Moscow, Russia, 123995 (Sergey R. Gilyarevskiy, MD, PhD, Professor at the Department of Clinical Pharmacology and Therapy at Russian Medical Academy of Advanced Studies).
Russian Federation
Corresponding author: Russian Medical Academy of Advanced Studies, 2/1 Barrikadnaya st., Moscow, Russia, 123995 (Sergey R. Gilyarevskiy, MD, PhD, Professor at the Department of Clinical Pharmacology and Therapy at Russian Medical Academy of Advanced Studies).
I. M. Kuzmina
Research Institute of the Emergency Care named after N.V. Sklifosofskiy, Moscow
Russian Federation
Russian Federation
M. V. Golshmid
Russian Medical Academy of Advanced Studies, Moscow
Russian Federation
Russian Federation
I. I. Sinitsina
Russian Medical Academy of Advanced Studies, Moscow
Russian Federation
Russian Federation
G. U. Zakharova
Russian Medical Academy of Advanced Studies, Moscow
Russian Federation
Russian Medical Academy of Advanced Studies, Moscow
Russian Federation
Russian Medical Academy of Advanced Studies, Moscow
References
1. Schwartz G.G., Olsson A.G., Ezekowitz M.D. et al. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial // J. Am. Med. Assoc. — 2001. — Vol. 285, № 13. — P. 1711–1718.
2. Nainggolan L. Is MIRACL a miracle or not? — [Electronic resource]. — Available at: www.theheart.org/article/196489.do. Fri, 17 Nov 2000.
3. McAlister F.A., Wiebe N., Ezekowitz J.A. et al. Metaanalysis: beta-blocker dose, heart rate reduction, and death in patients with heart failure // Ann. Intern. Med. — 2009. — Vol. 150, № 11. — P. 784–794
4. Swedberg K., Komajda M., Bohm M. et al. Effects on outcomes of heart rate reduction by ivabradine in patients with congestive heart failure: is there an infl uence of beta-blocker dose? Findings From the SHIFT (Systolic Heart failure treatment with the If inhibitor ivabradine Trial) Study // J. Am. Coll. Cardiol. — 2012. — Vol. 59, № 22. — P. 1938–1945.
5. Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high risk patients // N. Engl. J. Med. — 2000. — Vol. 342. — P. 145–153. [Erratа, N. Engl. J. Med. — 2000. — Vol. 342, № 10. — P. 784; Vol. 342, № 18. — Р. 1376.]
6. Fox K.M., EURopean trial On reduction of cardiac events with Perindopril in stable coronary Artery disease Investigators. Effi cacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, doubleblind, placebo-controlled, multicentre trial (the EUROPA study) // Lancet. — 2003. — Vol. 362, № 9386. — P. 782–788.
7. Nissen S.E., Tuzcu E.M., Libby P. et al. Effect of antihypertensive agents on cardiovascular events in patients with coronary disease and normal blood pressure // J. Am. Med. Assoc. — 2004. — Vol. 292, № 18. — P. 2217–2226.
8. Braunwald E., Domanski M.J., Fowler S.E. et al. Angiotensin-converting-enzyme inhibition in stable coronary artery disease // N. Engl. J. Med. — 2004. — Vol. 351, № 20. — P. 2058–2068.
9. Marre M., Lievre M., Chatellier G. et al. Effects of low dose ramipril on cardiovascular and renal outcomes in patients with type 2 diabetes and raised excretion of urinary albumin: randomised, double blind, placebo controlled trial (the DIABHYCAR study) // Br. Med. J. — 2004. — Vol. 328, № 7438. — P. 495–500.
10. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. The Acute Infarction Ramipril Effi cacy (AIRE) Study Investigators // Lancet. — 1993. — Vol. 342, № 8875. — P. 821–828.
11. van Vark L.C., Bertrand M., Akkerhuis K.M. et al. Angiotensin-converting enzyme inhibitors reduce mortality in hypertension: a meta-analysis of randomized clinical trials of renin-angiotensin-aldosterone system inhibitors involving 158,998 patients // Eur. Heart J. — 2012. — Vol. 33, № 16. — P. 2088–2097.
12. Yan X.W., Investigators for the study on the tolerability of perindopril. The study on the tolerability of perindopril in patients with stable coronary heart disease // Zhonghua Xin Xue Guan Bing Za Zhi. — 2007. — Vol. 35, № 12. — P. 11301132.
13. Butt D.A., Mamdani M., Austin P.C., Tu K., Gomes T., Glazier R.H. The risk of hip fracture after initiating antihypertensive drugs in the elderly // Arch. Intern. Med. — 2012. — Vol. 172, № 22. — P. 1739–1744.
14. Beckett N.S., Peters R., Fletcher A.E. et al. Treatment of hypertension in patients 80 years of age or older // N. Engl. J. Med. — 2008. — Vol. 358, № 18. — P. 1887–1898.
15. Ogilvie R.I., Anand S., Roy P., De Souza S. Perindopril for control of blood pressure in patients with hypertension and other cardiovascular risk factors: an open-label, observational, multicentre, general practice-based study // Clin. Drug Investig. — 2008. — Vol. 28, № 11. — P. 673–686.
16. Savarese G., Costanzo P., Cleland J.G. et al. A meta-analysis reporting effects of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in patients without heart failure // J. Am. Coll. Cardiol. — 2013. — Vol. 61, № 2. — P. 131–142.
17. Moher D., Liberati A., Tetzlaff J., Altman D.G.; PRISMA Group. Preferred reporting items for systematic reviews and metaanalyses: the PRISMA statement // J. Clin. Epidemiol. — 2009. — Vol. 62, № 10. — P. 1006–1012.
Review
For citations:
Gilyarevskiy S.R., Kuzmina I.M., Golshmid M.V., Sinitsina I.I., Zakharova G.U. TARGET DOSES OR TARGET PARAMETERS: WHAT IS PIVOTAL FOR CARDIOVASCULAR RISK DECREASE? "Arterial’naya Gipertenziya" ("Arterial Hypertension"). 2013;19(3):204-211. (In Russ.) https://doi.org/10.18705/1607-419X-2013-19-3-204-211
Views:
1178
Email this article 